Developing science,
delivering therapies

4d

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach
developing-science

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do
delivering-therapies

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate its lead oncology candidate, MRx0518, in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with advanced malignancies who have previously responded and whose disease has then progressed on PD-1/PD-L1 inhibitors. These are the first observations from an oncology study in man involving a Live Biotherapeutic Product.
4D pharma plc today announces that the Company has entered into a research collaboration and option to license agreement with MSD to discover and develop Live Biotherapeutics for vaccines
4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

BACK TO TOP